


IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/691,672
				Filing Date	November 12, 2003
				First Named Inventor	Pierre Druilhe
				Art Unit	1653
				Examiner Name	Not assigned
Sheet	1	of	1	Attorney Docket Number	02356.0085



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
B6		WO 02/092628 A2	11.21.92	Pierre Druilhe	Abstract	French
B6		WO 2004/043488 A1	5.27.04	Theisen et al.		


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
B6		International Search Report for corresponding PCT application No. PCT/EP02/012910	
B6		Theisen et al.; A plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies; Internet Article Online (October 2003) pp. 1-17.	
B6		Theisen et al.; A plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies; Vaccine, Vol. 22, No. 9 (March 2004) pp. 1188-1198	
B6		Carvalho et al.; IM-95 Immunization of salmire sciureus monkeys with MSP-3 and GLURP, two plasmodium falciparum antigens targets of protective antibodies; Mem do Instituto Oswaldo Cruz, Vol. 94, No. 11 (November 1999) pg. 216	
B6		Carvalho et al.; Malaria vaccine: candidate antigens, mechanisms, constraints and prospects, Scand. J. Immunol., Vol. 56 (2002) pp. 327-343	
B6		Bredmose et al.; Development of a heterologous gene expression system for use in lactococcus lactis, Recombinant Protein Production with Prokaryotic and Eukaryotic Cells, pp. (2001) 269-275	
		<del>Theisen et al.; The glutamate-rich protein (GLURP) of plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro; Infection and Immunity, Vol. 66, No. 1 (January 1998) pp. 11-17.</del>	
B6		Theisen et al.; Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein; Infection and Immunity, Vol. 72, No.1 (January 2004) pp. 247-252	
B6		Carvalho et al; Immunization of salmire sciureus monkeys with plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels; Scandinavian Journal of Immunology, Vol. 59, No. 4 (April 2004) pp. 363-372	

Examiner Signature		Date Considered	8-18-05
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02356.0085	Appln. No.	10/691,672
Applicant	Pierre DRUILHE		
Filing Date	November 12, 2003	Group:	Not assigned



U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
B6	P. Druilhe, et al.; <i>In vivo veritas</i> : lessons from immunoglobulin-transfer experiments in malaria patients; Annals of Tropical Medicine and Parasitology, (1997) 91(1) pgs. S37-S53
B6	C. Oeuvray, et al.; A novel merozoite surface antigen of <i>Plasmodium falciparum</i> (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies, Mem. Inst. Oswaldo Cruz, Rio de Janeiro (1994) 89(II) pg. 77-80
B6	E. Badell, et al.; Human malaria in immunocompromised mice: an <i>in vivo</i> model to study defense mechanisms against <i>Plasmodium falciparum</i> , J. Exp. Med. (Dec. 2000) 192(11) pgs. 1653-1659
B6	M. Blackman, et al.; A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies, J. Exp. Med. (July 1990) Vol. 172, pgs. 379-382
B6	H. Bouharoun-Tayoun, et al.; Mechanisms underlying the monocyte-mediated antibody-dependent killing of <i>Plasmodium falciparum</i> Asexual blood stages, J. Exp. Med. (August 1995) Vol. 182, pgs. 409-418
B6	D. Dodo, et al.; Levels of antibody to conserved parts of <i>Plasmodium falciparum</i> merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria; Infect. and Immun. (May 1999) 67(5) pgs. 2131-2137
B6	H. Israelsen et al.; Cloning and partial characterization of regulated promoters from <i>Lactococcus lactis</i> Tn917- <i>lacZ</i> integrants with the new promoter probe vector, pAK80, Applied and Environmental Microbiology, (July 1995) 61(7) pgs. 2540-2547
B6	S. Khusmith, P. Druilhe; Cooperation between antibodies and monocytes that inhibit <i>in vitro</i> proliferation of <i>Plasmodium falciparum</i> ; Infect. and Immun. (July 1983) 41(1) pgs. 219-223
B6	F. Lunel, P. Druilhe; Effector cells involved in nonspecific and antibody-dependent mechanisms directed against <i>Plasmodium falciparum</i> blood stages <i>in vitro</i> ; Infect. and Immun. (July 1989) 57(7) pgs. 2043-2049
B6	V. Marshall et al.; Close linkage of three merozoite surface protein genes on chromosome 2 of <i>Plasmodium falciparum</i> ; Molecular and Biochemical Parasitology (1998) Vol. 94, pgs. 13-25

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02356.0085	Appln. No.	10/691,672
Applicant	Pierre DRUILHE		
Filing Date	November 12, 2003	Group:	Not assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
30	D. McColl, R.Anders; Conservation of structural motifs and antigenic diversity in the <i>Plasmodium falciparum</i> merozoite surface protein-3 (MSP-3); Molecular and Biochemical Parasitology, (1997) Vol. 90, pgs. 21-31
30	C. Oeuvray et al.; Merozoite surface protein-3: a malaria protein inducing antibodies that promote <i>Plasmodium falciparum</i> killing by cooperation with blood monocytes; Blood (September 1994) 84(5), pgs. 1594-1602
30	C. Oeuvray et al.; Cytophilic immunoglobulin responses to <i>Plasmodium falciparum</i> glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal, Infect. and Immun. (May 2000) 68(5) pgs. 2617-2620
30	R. Pleass, J.Woof; Fc receptors and immunity to parasites; Trends I Parasitology (November 2001) 17(11) pgs. 545-551
30	M. Theisen et al.; The glutamate-rich protein (GLURP) of <i>Plasmodium falciparum</i> is a target for antibody-dependent monocyte-mediated inhibition of parasite growth <i>in vitro</i> ; Infect. and Immun. (Jan. 1998) 66(1) pgs. 11-17

Examiner	BEJ	Date Considered	8-18-05
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce	